Megan Brooks Frexalimab (Sanofi), a novel, investigational second-generation inhibitor of the CD40 ligand, significantly reduced disease activity in relapsing multiple sclerosis (MS) and was well tolerated in a phase 2 study. At week 12, there was an 89% reduction in new gadolinium (Gd)-enhancing T1 brain lesions — a standard measure of active inflammation in MS...
Tag: <span>frexalimab</span>
Post
Study finds frexalimab has favorable effect on relapsing multiple sclerosis
by Elana Gotkine For patients with relapsing multiple sclerosis, the anti-CD40L monoclonal antibody frexalimab has a favorable effect on the number of new gadolinium-enhancing T1-weighted lesions, according to a study published in the Feb. 15 issue of the New England Journal of Medicine.Patrick Vermersch, M.D., Ph.D., from the University of Lille in France, and colleagues...